Business & Finance

Enzo Biochem reports improved first quarter financial results

Published in Lab Law Weekly, January 12th, 2007

Enzo Biochem, Inc. (ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, reported operating results for the first quarter of fiscal 2007 ended October 31, 2006.

Net revenues for the quarter amounted to $10.4 million, up 3% from $10.2 million in the corresponding year-ago quarter. Gross profit, including royalty income, amounted to $6.4 million, compared with $6.1 million a year ago. The net loss declined to $1.2 million, or $0.04 per fully diluted share, compared with a net loss of $3.3 million, or $0.10 per fully diluted share, in the previous year's fiscal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry